Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have been diagnosed with a blood cancer (such as multiple myeloma, non-Hodgkin lymphoma, or similar)
- Have started bispecific antibody treatment within the last 30 days
- Be able to understand and sign a consent form
- Be willing to have infections tracked for up to one year of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies new treatments called bispecific antibodies for multiple myeloma, a type of blood cancer. These therapies aim to help patients who have had their disease come back after other treatments.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
This study looks at blood samples from people with B-cell lymphoma or multiple myeloma who are getting CAR-T cell therapy. The goal is to find signs in the blood that might predict how well the treatment works, which could help improve care for future patients.
This trial tests whether adding a drug called emapalumab can reduce common side effects (cytokine release syndrome and nerve problems) in people receiving bispecific antibody therapy for lymphoma or multiple myeloma. If you're planning to start this treatment, joining may help make it safer and more tolerable.
This study tracks patients who have received CAR-T cell therapy to learn more about infections that may happen after treatment. It aims to improve care and outcomes for people with certain blood cancers.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Hear when a new Severe Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.